Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    +1.76 (+2.16%)
     
  • Gold

    2,254.80
    +42.10 (+1.90%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0793
    -0.0036 (-0.33%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • dólar/libra

    1.2624
    -0.0014 (-0.11%)
     
  • USD/JPY

    151.4020
    +0.1560 (+0.10%)
     
  • Bitcoin USD

    70,873.30
    +1,586.52 (+2.29%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

AstraZeneca's Nirsevimab Shows Favorable Safety, Tolerability Profile In Infants At High Risk Of RSV

  • AstraZeneca Plc (NASDAQ: AZN) announced data from the MEDLEY Phase 2/3 trial evaluating nirsevimab in infants at high risk of respiratory syncytial virus (RSV).

  • The trial assessed the safety and tolerability of nirsevimab compared to Sobi's Synagis (palivizumab) in infants with chronic lung disease, congenital heart disease, and/or prematurity.

  • RSV is a common, contagious pathogen that causes seasonal epidemics of lower respiratory tract infections (LRTI), including bronchiolitis and pneumonia.

  • Nirsevimab, being developed by AstraZeneca and Sanofi SA (NASDAQ: SNY), showed a safety and tolerability profile comparable to the only available preventative option against lower respiratory tract infections (LRTI) caused by RSV, with one dose for the entire season.

  • The occurrence of treatment-emergent adverse events or treatment-emergent serious adverse events was similar between groups.

  • Full results from the MEDLEY trial will be presented at a forthcoming medical meeting. The trial is ongoing to collect additional safety data.

  • Nirsevimab is also being evaluated in the MELODY Phase 3 trial, which met its primary endpoint of a statistically significant reduction in the incidence of medically attended LRTI caused by RSV compared to placebo healthy late preterm and term infants.

  • The company plans regulatory submissions from the first half of 2022.

  • Price Action: AZN shares are up 0.62% at $59.72 during the premarket session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement